{"id":"W3088466047","doi":"10.1016/j.annonc.2020.08.2070","title":"799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Oncology; Placebo; Tolerability; Cisplatin; Adjuvant therapy; Urology; Chemotherapy; Randomized controlled trial; Adverse effect; Pathology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001185784,0.00217406,0.003718241,0.0004087043,0.0004596232,0.001286553,0.001127559,0.001991584,0.009933383],"category_scores_gemma":[0.001044376,0.000749414,0.001632316,0.0004201332,0.001271404,0.00127693,0.000415739,0.004226579,0.00209616],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006751081,"about_ca_system_score_gemma":0.001379293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009494532,"about_ca_topic_score_gemma":0.002508312,"domain_scores_codex":[0.9996291,0.0001371586,0.00002101512,0.00008838132,0.00002971151,0.00009460425],"domain_scores_gemma":[0.9996481,0.00006971176,0.00005726699,0.00003116362,0.00002591385,0.0001678322],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9533582,0.006063222,0.0003326007,0.001488885,0.001031439,0.00005985697,0.00005681701,0.0005687901,0.006924307,0.0003012151,0.003281699,0.02653295],"study_design_scores_gemma":[0.963425,0.03434652,0.0004940408,0.00002037588,0.000197746,0.0000320768,0.00001514426,0.0002990578,0.0003563416,0.0001462846,0.0006511284,0.0000162493],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9634461,0.01132401,0.002096916,0.002307208,0.002001819,0.007480719,0.003809151,0.0009672126,0.006566895],"genre_scores_gemma":[0.9717804,0.005176786,0.002453509,0.002610258,0.0005128825,0.005572017,0.003426558,0.0001085283,0.008359046],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009933383,"threshold_uncertainty_score":0.03323048,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06522590316561952,"score_gpt":0.3628403563382298,"score_spread":0.2976144531726103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}